BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Dr. Falk Pharma GmbH

Headquarters: Freiburg, Germany
Year Founded: 1960
Status: Private

BioCentury | Nov 5, 2024
Deals

Novo to use Ascendis’ TransCon for once-monthly GLP-1R agonist

Deals report: AbbVie-EvolveImmune, Genmab-Revitope and GSK-Chimagen partner for T cell engagers 
BioCentury | Aug 1, 2023
Deals

Pharma deals seek novelty with heavy focus on first in class

An analysis of the products, technologies and targets that have attracted global pharma deals over past 12 months
BioCentury | Oct 21, 2022
Politics, Policy & Law

Oct. 20 Quick Takes: Novartis commits first cancer therapy to UN patent pool

Plus: AbbVie gains LPAR1 antibody via $255M buy of DJS and updates for Denali, the U.K., Kite-Refuge, Takeda-Zedira, Immunic, Talaris, Celeris
BioCentury | Feb 27, 2019
Finance

Calypso finds its rhythm

How rising interest in IL-15 helped six-year-old Calypso close its series A
BioCentury | Jun 16, 2017
Company News

GeneriCo wins IPR for Apriso

BioCentury | Jul 11, 2016
Clinical News

Rifamycin SV MMX: Phase III data

BioCentury | Oct 12, 2015
Company News

Lipid Therapeutics, Nestle deal

BioCentury | Aug 17, 2015
Finance

Medigene remade

How Medigene found new investors by focusing exclusively on immunotherapy
BioCentury | May 25, 2015
Clinical News

Trichuris suis ova: Development discontinued

BioCentury | Nov 17, 2014
Clinical News

LT-02: Phase III started

Items per page:
1 - 10 of 71